Quantitative Structure-Activity Relationship (QSAR) Market Increasing Adoption of Modeling Tools in Drug Discovery
Quantitative Structure-Activity Relationship (QSAR) Market Insight
According to our new market research study on “Quantitative Structure-Activity Relationship (QSAR) Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Application and Industry, ” the market is expected to reach US$ 1,888.5 million in 2027 from US$ 1,388.1 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027. The market growth is mainly attributed to the increasing adoption rate of modeling tools in drug discovery and rising investments for drug discovery. However, low adoption rate of the technique in emerging countries is hindering the quantitative structure-activity relationship market growth.
The market growth is mainly attributed to the increasing adoption rate of modeling tools in drug discovery and rising economic for drug discovery . However, low adoption rate of the technique in emerging countries is hindering the quantitative structure-activity relationship market growth.
Get sample Research on Quantitative Structure-Activity Relationship (QSAR) Market study at: https://www.theinsightpartners.com/sample/TIPRE00018665/
Quantitative Structure-Activity Relationship (QSAR) Market Comparative Landscape and Key Development
Protoqsar Sl., Intertek Group Plc, Bibra Toxicology Advice And Consulting Ltd, Covance Inc. (Labcorp), Latham Biopharm Group, Nsf International, Creative Biolabs, Qsar Lab Sp. Z O, and Dassault Systèmes are among the companies operating in the quantitative structure-activity relationship market.
The COVID-19 pandemic is causing massive disruptions in supply chains, consumer markets, and economies across the world. However, the high demand for promising tools for rapid and accurate drugs and vaccine development has boosted the demand for QSAR, thereby fueling the market growth.
With the introduction of AI in the pharmaceuticals and healthcare sectors, the companies in these sectors are investing in collaborations with AI players for the development of better and advanced healthcare tools, which, in turn facilitates better identification of drug targets and aids in designing new drug candidates. Thus, a rise in number of partnerships between pharmaceutical industries and AI companies, and government organizations has been witnessed on the global scale. For instance, in 2019, the Royal Free London NHS Foundation Trust entered into a five-year partnership with DeepMind Technologies (Google), wherein the company is expected to assist the NHS in discovering therapies for the management of acute kidney injuries. The 100,000 Genomes Project of the UK is a global project that utilizes data and AI from NHS patients with rare diseases. The project also has Roche, Merck, and Biogen as partners.
Increasing Adoption of Modeling Tools in Drug Discovery
QSAR is a computational modeling method used to determine relationships between structural properties and biological activities of chemical compounds. The drug discovery and development, along with studying the potential therapeutic applications of the drug, is a complicated, expensive, and time-consuming process. Pharmaceutical and biopharmaceutical companies are adopting various computational methodologies such as QSAR to increase the efficiency of this entire process. In stages from hit identification to lead optimization, techniques such as ligand or structure-based virtual screening are widely being used by various pharmaceutical companies. With the help of modeling, existing data can be leveraged to gain insights into product safety and effectiveness. Owing to the efficiency of computational methods, the Foof and Drug Administration (FDA) and European Medicines Agency (EMA) have incorporated drug modeling to achieve efficient drug development.
QSARs have a substantial role in toxicity prediction, drug design, and environmental fate modeling of food & beverages, chemicals, and pharmaceuticals. Moreover, predictive QSAR models are used by different regulatory agencies to do the estimation of chemical, physical, and biological parameters of chemicals with the helps of specific applications that precisely performs the tasks of decision-making contexts in chemical safety assessment.
The quantitative structure-activity relationship (QSAR) market, based on application, is segmented into drug discovery, molecular modelling, chemical screening, regulatory and decision-making, and other applications. In 2019, the drug discovery segment held the largest share of the market, and it is further expected to register the highest CAGR in the market during the forecast period. The growth of the market for this segment is mainly credited to the rising adoption rate of technologies in drug discovery process.
The quantitative structure-activity relationship market, by industry, is segmented into pharmaceuticals, cosmetics, environmental, and food and beverages. In 2019, the pharmaceuticals segment held the largest share of the market, and the same segment is expected to register the highest CAGR in the market during 2020–2027.
Buy Complete Report of Quantitative Structure-Activity Relationship (QSAR) Market Study at: https://www.theinsightpartners.com/buy/TIPRE00018665/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Person: Sameer Joshi